{"id":"W4386948542","doi":"10.1016/j.ygyno.2023.06.523","title":"Pembrolizumab versus placebo in addition to carboplatin and paclitaxel for measurable stage 3 or 4a, stage 4b or recurrent endometrial cancer: The phase 3, NRG GY018 study (LBA 10)","year":2023,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Carboplatin; Medicine; Pembrolizumab; Endometrial cancer; Oncology; Paclitaxel; Internal medicine; Chemotherapy; Placebo; Stage (stratigraphy); Cancer; Pathology; Cisplatin; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001365197,0.001400056,0.002457577,0.0005258339,0.0003826727,0.001010516,0.0007729116,0.001400216,0.005999641],"category_scores_gemma":[0.001160118,0.0005230986,0.001968419,0.0003782852,0.0007765779,0.001363734,0.0003334984,0.003370988,0.001137292],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008209031,"about_ca_system_score_gemma":0.001062758,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001538349,"about_ca_topic_score_gemma":0.00402467,"domain_scores_codex":[0.999603,0.0001914467,0.00002067589,0.00007463546,0.00002274172,0.00008744671],"domain_scores_gemma":[0.9995204,0.000135804,0.00009345482,0.0000302269,0.00002173401,0.0001984737],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9633125,0.006336618,0.0004393529,0.0004045818,0.0008146258,0.00003432851,0.0000428643,0.0003826832,0.003488853,0.00009451659,0.001216729,0.0234323],"study_design_scores_gemma":[0.8679441,0.1248292,0.00398428,0.00005610615,0.0007639586,0.00005242507,0.0000355698,0.0005234242,0.0005949497,0.0001968778,0.001002279,0.00001690043],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9852174,0.006372045,0.0005055058,0.0009313662,0.0007049143,0.001246686,0.001332461,0.0001744564,0.003515149],"genre_scores_gemma":[0.9866968,0.003323361,0.001004668,0.001212543,0.0003960122,0.001413412,0.001218939,0.00002859217,0.004705794],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005999641,"threshold_uncertainty_score":0.02007085,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1841982525081639,"score_gpt":0.4523627754498964,"score_spread":0.2681645229417325,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}